Susquehanna International Group, LLP Ideaya Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 15, 2024
SELL
$34.37 - $43.46 $305,893 - $386,794
-8,900 Reduced 39.56%
13,600 $477,000
Q1 2024

May 07, 2024
BUY
$34.2 - $47.13 $171,000 - $235,650
5,000 Added 28.57%
22,500 $987,000
Q4 2023

Feb 14, 2024
BUY
$24.59 - $35.83 $71,311 - $103,907
2,900 Added 19.86%
17,500 $622,000
Q3 2023

Nov 14, 2023
BUY
$21.07 - $29.77 $86,387 - $122,057
4,100 Added 39.05%
14,600 $393,000
Q2 2023

Aug 11, 2023
BUY
$13.33 - $25.53 $139,965 - $268,065
10,500 New
10,500 $246,000
Q4 2022

Feb 14, 2023
SELL
$14.47 - $18.17 $383,455 - $481,505
-26,500 Reduced 29.61%
63,000 $1.14 Million
Q2 2022

Aug 15, 2022
BUY
$8.28 - $13.88 $586,224 - $982,704
70,800 Added 378.61%
89,500 $1.24 Million
Q1 2022

May 16, 2022
BUY
$11.18 - $24.02 $33,540 - $72,060
3,000 Added 19.11%
18,700 $209,000
Q4 2021

Feb 14, 2022
SELL
$20.95 - $26.88 $800,290 - $1.03 Million
-38,200 Reduced 70.87%
15,700 $371,000
Q3 2021

Nov 15, 2021
BUY
$17.26 - $27.08 $930,314 - $1.46 Million
53,900 New
53,900 $1.37 Million
Q2 2021

Aug 11, 2021
SELL
$17.76 - $24.83 $394,272 - $551,226
-22,200 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$13.48 - $23.77 $299,256 - $527,694
22,200 New
22,200 $522,000

Others Institutions Holding IDYA

# of Institutions
206
Shares Held
73.6M
Call Options Held
21.5K
Put Options Held
20.3K
View Full List

About IDEAYA Biosciences, Inc.

IDYA Quotes by TradingView
  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.52B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email